|
J Biol Chem, Vol. 275, Issue 20, 15271-15278, May 19, 2000
Hrs-2 Regulates Receptor-mediated Endocytosis via
Interactions with Eps15*
Andrew J.
Bean ,
Svend
Davanger§,
Marian F.
Chou,
Brenda
Gerhardt,
Susan
Tsujimoto, and
YuChieh
Chang
From the Department of Neurobiology and Anatomy, and The W. M. Keck Center for the Neurobiology of Learning and Memory, University of
Texas Medical School, Houston, Texas 77030 and the
§ Department of Cell Biology and Anatomy, University of
Bergen, Bergen 5009, Norway
 |
ABSTRACT |
Hrs-2, via interactions with SNAP-25, plays a
regulatory role on the exocytic machinery. We now show that Hrs-2
physically interacts with Eps15, a protein required for
receptor-mediated endocytosis. The Hrs-2/Eps15 interaction is calcium
dependent, inhibited by SNAP-25 and -adaptin, and results in the
inhibition of receptor-mediated endocytosis. Immunoelectron microscopy
reveals Hrs-2 localization on the limiting membrane of multivesicular bodies, organelles in the endosomal pathway. These data show that Hrs-2
regulates endocytosis, delineate a biochemical pathway
(Hrs-2-Eps15-AP2) in which Hrs-2 functions, and suggest that Hrs-2 acts
to provide communication between endo- and exocytic processes.
 |
INTRODUCTION |
Initial attempts to understand the molecular basis of exocytosis
involved the characterization of proteins present on synaptic vesicles
and on the presynaptic plasma membrane (1-3). These studies revealed a
series of protein-protein interactions that have been suggested to
mediate events leading to the fusion of vesicles with the plasma
membrane (1-4). SNAP-251 is
associated with the plasma membrane and binds to both syntaxin (found
on the plasma membrane) and VAMP (found on the vesicle) (4-7). Through
these interactions SNAP-25 is a critical component of a protein complex
(7 S) that is proposed to be necessary for fusion of synaptic vesicles
with the plasma membrane (4, 6-9).
Hrs-2 is an ATPase that physically associates with SNAP-25 in a
calcium-regulated manner (10). Hrs-2 binds to SNAP-25 through its
second coiled-coil domain and does not directly interact with either
syntaxin or VAMP (11). When Hrs-2 is bound to the complex of SNAP-25
and syntaxin, VAMP binding to SNAP-25 is inhibited, reducing the amount
of 7 S complex formed (11). Thus, Hrs-2, via interaction with SNAP-25,
may play a negative regulatory role on the exocytic machinery that is
alleviated when calcium concentrations are elevated, dissociating Hrs-2
from the Hrs-2·SNAP-25·syntaxin complex and allowing VAMP to bind
to SNAP-25/syntaxin.
Ultrastructural and physiological experiments have identified at least
two endocytic pathways: a rapid clathrin-independent pathway, and a
slower clathrin-dependent pathway (12-21). Clathrin triskelia form cages that capture vesicle membrane for retrieval during
the endocytic process (14, 22, 23). Clathrin and its adapter proteins
(AP2 and AP180 are recruited to the plasma membrane and link clathrin
to the membrane) along with other binding partners (e.g.
dynamin and amphiphysin) appear to be involved in early events in the
endocytic pathway related to vesicle budding and maturation (14,
22-29). Other proteins necessary for endocytosis have been found in
genetic screens as well as by using biochemical methods. Eps15 is the
prototypical member of a family of proteins containing EH motifs that
bind to NPF domains in target proteins (30-37). Eps15 contains three
amino-terminal EH domains, a central coiled-coil region, and 15 COOH-terminal DPF repeats (32, 33). Eps15 is localized to components of
the endocytic pathway (38) and has been shown to be essential for
receptor-mediated endocytosis through interactions with -adaptin
(35, 39). The yeast homolog of Eps15, Pan1p, is an EH domain-containing
protein found in Saccharomyces cerevisiae that is required
for endocytosis (31, 40). Additionally, Pan1p binds to another
EH-containing protein, END3p, as well as the yeast homolog of AP180,
and has genetic interactions with synaptojanin and a ubiquitin-protein
ligase (31, 40).
Exocytosis and endocytosis are closely linked and temporally
coordinated during the vesicle cycle. These two distinct events must be
regulated precisely such that they occur sequentially in order to
maintain the fidelity of vesicle-mediated secretion and cellular
architecture. However, the molecular mechanisms that coordinate these
events remain elusive. The protein machinery involved in endocytosis
and exocytosis is a likely substrate for their interaction. We have
found that Hrs-2, a protein implicated in regulation of the formation
of the SNAP-25·syntaxin·VAMP complex, interacts with Eps15, a
protein necessary for clathrin-mediated endocytosis. The interaction of
Hrs-2 with Eps15 is calcium dependent, is inhibited by SNAP-25 and
-adaptin, and results in the inhibition of receptor-mediated
endocytosis. Moreover, the inhibition of endocytosis produced by
expression of Hrs-2 is rescued by coexpression of -adaptin. These
data show that Hrs-2 has a regulatory role in endocytosis, delineate a
biochemical pathway (Hrs-2-Eps15-AP2) in which Hrs-2 functions, and
suggest a mechanism by which exocytosis and endocytosis are linked.
 |
EXPERIMENTAL PROCEDURES |
Two-hybrid Assay--
Full-length rat Hrs-2 was subcloned into
the pGBT vector and used to screen a human brain cDNA library
inserted downstream of the GAL4 activation domain in the pGAD10 vector
(CLONTECH). Yeast strains (SFY526, HF7c) used
herein have been previously characterized (S. Fields,
CLONTECH). All constructions were verified by
sequencing (Sequenase). 3.06 × 106 independent clones
were screened by sequential transformation with pGBT/Hrs-2 and
pGAD/library followed by plating on agar containing yeast nitrogen base
(6.7 g/liter, Difco), dextrose (2%), and an amino acid mixture lacking
histidine, leucine, tryptophan, and uracil and stored at 30 °C in
the dark. Five-12 days after plating, large colonies (>3 mm diameter,
n = 190) were replica plated onto new plates and
-galactosidase activity was assessed on filter lifts. Single
colonies from clones that turned blue within 1 h (n = 40) were grown overnight in SD medium lacking
leucine, tryptophan, and histidine and DNA was extracted. DNA was
electroporated into HB101 Escherichia coli cells, and DNA
was isolated from single colonies. After restriction digests confirmed
the presence of the activation domain plasmid, multiple
co-transformations were performed with the candidate DNA and the
pGBT9/Hrs-2, as well as pGBT9/p53. Clones that reacted positively for
-galactosidase activity with the pGBT9/Hrs-2 but not either by
themselves or with the control plasmids containing the binding domain
alone or the binding domain fused to the tumor supressor gene p53, were considered for further study (n = 36). Sequencing
revealed a single clone whose sequence was identical to SNAP-25b and a
single clone identical to human Eps15 (amino acids 416-858). Other
clones remain to be analyzed.
Immunoprecipitation--
Hrs-2 monoclonal antibody or purified
mouse IgG was cross-linked to Protein A-agarose using
dimethylpimelimidate. Rat brain postnuclear supernatant was precleared
with protein A-agarose and incubated with either anti-Hrs-2 or mouse
IgG overnight at 4 °C. Following four washes with PBS-T, samples
were boiled in sample buffer and separated using SDS-PAGE. Proteins
were transferred to membranes that were probed with Eps15 (Santa Cruz
Biotech) or Hrs-2 (41) antibodies.
Production of Recombinant Proteins--
Full-length Hrs-2 was
subcloned into Hta baculovirus vector (Life Technologies, Inc.), and
Hrs-2 virus was produced according to the manufacturer's protocol.
Hrs-2 protein was produced by infecting a 500-ml culture of Sf21
cells at a multiplicity of infection of 0.1. Post-infection (72-96 h),
cells were harvested by centrifugation, and pellets were frozen.
Proteins were extracted by incubation (60 min at 4 °C) with 5%
betaine in 10 mM Tris, pH 7.5, 1 mM EGTA, 1 mM EDTA, and a mixture of protease inhibitors including
aprotinin, pepstatin, and phenylmethylsulfonyl fluoride, affinity
isolated using Ni-NTA-agarose (Qiagen), and eluted from the resin when
necessary, using 250 mM imidazole. Hrs-2 truncations were
produced as described (11). GFP fusion proteins were produced in pEGFP
(CLONTECH) by direct transfer from the GST vector.
Hrs-2 eps was produced by partial digestion of pEGFP-Hrs-2 with
PstI removing amino acids 258-484. Using the two-hybrid
technique we have observed that the Hrs-2 eps protein does not bind
to Eps15 although it does bind to SNAP-25 and full-length Hrs-2 (data
not shown).
SNAP-25 was subcloned into pGEX-KG and grown at 37 °C in the AB1899
strain of E. coli. Full-length GST-Eps15 was a kind gift of
A. E. Salcini and P. DiFiore, while deletion constructs of Eps15
were a kind gift of A. Benmerah and N. Cerf-Bensussan. All constructs
were grown in BL21 cells at 37 °C. After reaching mid-log phase,
isopropyl-1-thio- -D-galactosidase (300 µM)
was added, and cells were incubated for an additional 3 h. Cells
were harvested by centrifugation, lysed in a French Press, and protein
was affinity isolated using glutathione-agarose.
In Vitro Binding--
Eps15/GST (0.3 µM) bound to
glutathione beads was incubated with the indicated amount of
recombinant Hrs-2 protein for 60 min at 4 °C in either: 10 mM Hepes-KOH, pH 7.5, 140 mM KoAc, 1 mM MgCl2, 0.1 mM EGTA, 0.1%
gelatin, 0.05% Tween 20 or the same buffer containing either 2 mM EGTA and various concentrations of Ca2+,
Ba2+, or Sr2+. Beads were washed 3 times with
PBS-T, and the proteins remaining on the beads were solubilized in 15 µl of sample buffer. Samples were separated using SDS-polyacrylamide
gels and transferred to nitrocellulose. Western blotting was performed
using anti-Hrs-2 antibodies followed by 125I-labeled
secondary antibody and quantitated by phosphorimaging. The
EC50 is defined as half-maximal binding of each soluble
protein based on optical density obtained by phosphorimaging (Molecular Dynamics model 300A).
For saturation binding, various concentrations of Hrs-2 were incubated
(4 °C for 60 min) with glutathione-agarose beads containing either
glutathione S-transferase or Eps15. To determine interacting domains, various Hrs-2 or Eps15 fragments were purified and incubated (4 °C for 60 min) with either Eps15 or Hrs-2, respectively. For complex formation studies Hrs-2 bound to Ni-agarose was incubated with
Eps15 alone or Eps15 and various concentrations of SNAP-25 at 4 °C
for 60 min. To determine whether Ca2+ had an effect on
Hrs-2/Eps15 interactions, single concentrations of Hrs-2 were incubated
with Eps15 bound to glutathione-agarose (4 °C for 60 min) in the
presence of various concentrations of free Ca2+ (buffered
with 2 mM EGTA and calculated using WebMaxCalc version 1.1). Free Ba2+ or Sr2+ (0.5 mM)
were used to examine selectivity. To examine the effect of -adaptin
on Hrs-2/Eps15 binding, Eps15 was immobilized on glutathione-agarose
and then incubated with -adaptin bacterial lysate. The
Eps15-agarose, with or without with -adaptin, was then incubated
with increasing concentrations of Hrs-2. Following binding incubations,
reactions were washed 3 times with PBS containing 0.05% Tween 20, and
SDS sample buffer was added to the beads. Proteins bound to the beads
were separated by SDS-PAGE and subjected to immunoblot analysis using
anti-Hrs-2 antibodies and either horseradish peroxidase- or
125I-labeled secondary antisera.
Immunohistochemistry--
For electron microscopic
immunohistochemical localization, rats were perfused with 3%
paraformaldehyde, 0.1% glutaraldehyde, 0.2% picric acid in 0.1 M phosphate buffer. Brains were post-fixed in
situ and sectioned on a vibratome. Tissues were embedded in Lowecryl and thin sectioned. Embedded tissues were incubated with Hrs-2
antibody (10) (1:200), anti-rabbit secondary antibody conjugated to 1.4 nm gold particles (nanogold 2004, Nanoprobes, Stony Brook, NY), and
silver intensified (Nanoprobes). Cells were examined on an electron
microscope (Jeol) and photographed.
Receptor-mediated Endocytosis--
HeLa cells were maintained in
Dulbecco's modified Eagle's medium with 10% fetal calf serum and
penicillin/streptomycin. Cells were plated onto coverslips and
transiently transfected (Qiagen, effectene transfection reagent) with
pEGFP, pEGFP-Hrs-2, pEGFP-Hrs-2 Eps15, pEGFP-Hrs-2 fragments,
pCDNA3- -adaptin or pEGFP-Hrs-2+pCDNA3- -adaptin 24 h
prior to endocytosis experiments. To examine receptor-mediated endocytosis, transfected HeLa cells were serum starved for 1 h prior to incubation (10 min at 4 °C followed by 3 washes with media)
with Alexa 594-conjugated transferrin. After the chamber temperature
was heated back to 37 °C, images were acquired on a Zeiss Aviovert
microscope with a Hamamatsu ORCA CCD camera between 5 and 20 min
post-warming. Experiments using pCDNA3- -adaptin were performed
identically except that after the unbound transferrin was washed, the
cells were fixed in 4% paraformaldehyde for 10 min and then washed
three times in PBS. The -adaptin was visualized using a monoclonal
antibody (Sigma) and cy-5 secondary antibody on a Bio-Rad 1024 confocal
microscope. Image analysis was performed on a Macintosh computer using
the public domain NIH Image program (version 1.62) and consisted of
outlining cells and computing the area and mean gray value of the
region of interest. This computation was performed after the threshold
was set automatically based on an analysis of the histogram of the
region of interest. Data are presented in units of integrated density
(area of the cells × mean pixel volume) and are normalized to
untransfected cells for graphical representation. The number of cells
analyzed from each group is listed in the figure legend. Differences
between groups were analyzed using ANOVA with post-hoc Dunnetts test.
 |
RESULTS |
Hrs-2 Interacts with Eps15--
Using full-length Hrs-2 as bait in
a two-hybrid screen, we recovered a cDNA clone identical to amino
acids 416-858 of human Eps15. The interaction appeared specific as it
was not observed using either p53 or GAL4 as bait (data not shown). To
confirm the two-hybrid result we obtained the rat Eps15 clone, produced the recombinant protein, and performed binding assays using purified Hrs-2 and Eps15 (Fig. 1A).
Hrs-2 binding to immobilized Eps15 approached saturation with an
apparent EC50 for binding of ~1.8 µM. These
data suggest that Hrs-2 interacts with Eps15 directly in the absence of
other protein components.

View larger version (43K):
[in this window]
[in a new window]
|
Fig. 1.
Characterization of Hrs-2 interaction with
Eps15. A, recombinant Hrs-2 binding to immobilized
Eps15. Eps15 (0.3 µM) was immobilized on glutathione
beads and incubated with increasing concentrations of Hrs-2. Hrs-2 did
not bind to GST bound to glutathione-agarose (see graph). The
EC50 (affinity is reported as the 50% effective
concentration (EC50), the concentration of protein at which
half-maximal binding occurs, instead of Kd, since
the washing phase of these in vitro binding assays is
conducted under non-equilibrium conditions) of Hrs-2 for immobilized
Eps15 is 1.8 µM, and the stoichiometry is 0.1-0.4:1
(Eps15:Hrs-2) depending on which protein is immobilized. B,
coimmunoprecipitation of Eps15 and Hrs-2. Brain post-nuclear
supernatant (PNS) containing Eps15 and Hrs-2 (lane
1) was incubated with anti-Hrs-2 antibodies (lane 2) or
purified mouse IgG (lane 3). The co-precipitation of Eps15
and Hrs-2 from brain confirms the interaction observed using the
two-hybrid system and binding of recombinant fusion proteins (in
A). C, five GST-Hrs-2 fusion proteins
encompassing residues 1-478 (A), 1-449 (B),
216-449 (C), 450-478 (D), and 515-562
(E, depicted in the schematic diagram, top) were
generated by bacterial expression, immobilized on glutathione-agarose
beads, and assayed for binding interactions with full-length Eps15.
Eps15 binds to Hrs-2 truncation mutants that contain the region between
the FYVE finger and the first coiled-coil domain (216-449, lanes
A-C). Neither of the two coiled-coil regions (lanes D
and E) were able to bind Eps15. These data suggest that the region between the FYVE
finger and the first coiled-coil domain of Hrs-2 is necessary and
sufficient to bind Eps15. D, five GST-Eps15 fusion proteins
encompassing residues 1-320 (DI), 320-529
(DII), 529-896 (DIII), 529-763
(DIII0), and 529-618 (DIII3) (depicted in
schematic diagram, top) were expressed in BL21 cells,
immobilized on glutathione-agarose beads, and assayed for binding
interactions with full-length Hrs-2. Hrs-2 binds to both DII and DIII
but not to DI. Truncation mutants of DIII were used to determine that
Hrs-2 binds in the region required for -adaptin binding and not in
other regions of Eps15. Thus, either the coiled-coil region
(DII) or the AP2-binding domain of Eps15 is sufficient for
Hrs-2 binding.
|
|
Eps15 from brain postnuclear supernatant was found to
coimmunoprecipitate with Hrs-2 (Fig. 1B). Thus, while Eps15
was bound to protein A-Sepharose to which Hrs-2 antibody had been
cross-linked (lane 2), Eps15 was not detected on protein
A-Sepharose containing a control antibody, mouse IgG (lane
3). These data support the two-hybrid data and confirm
that Hrs-2 can interact with Eps15 from brain.
We used truncated forms of the recombinant proteins to determine the
domains of Hrs-2 and Eps15 that mediate the interaction between these
molecules. To determine the domain of Hrs-2 that binds to Eps15, we
constructed a set of GST fusion proteins containing regions of Hrs-2
predicted to form structural motifs (Fig. 1C, top). These
truncation mutants were expressed, bound to glutathione-agarose beads,
and then examined for interaction with full-length soluble Eps15 during
an in vitro binding assay. As shown in Fig. 1C
(bottom), Eps15 bound to Hrs-2 truncations that contained
the region between the FYVE zinc finger region and the first
coiled-coil domain, and not to GST beads alone or to either of the
coiled-coil regions. Since Eps15 was able to bind to the Hrs-2
truncation containing amino acids 216-449, we conclude that this
region of Hrs-2 is both necessary and sufficient for the binding of
Eps15.
In a similar manner, we determined the domain of Eps15 that binds to
Hrs-2 (Fig. 1D). GST fusion proteins containing regions of
Eps15 were expressed, immobilized on glutathione-agarose, and then
assayed for interaction with full-length Hrs-2. Hrs-2 bound to both the
coiled-coil domain and the carboxyl-terminal domain of Eps15 that
contains NPF repeats (Fig. 1D). Moreover, the region in the
carboxyl-terminal domain necessary for Hrs-2 binding was delineated
using additional deletion constructs of that region and found to
correspond to the region required for -adaptin binding to Eps15
(Fig. 1D). The amino-terminal EH domain construct was unable
to interact with Hrs-2. Thus, we conclude that Eps15 contains two
domains capable of interaction with Hrs-2, the coiled-coil motif, as
well as the -adaptin binding region in the COOH-terminal domain.
The Interaction of Hrs-2 with Eps15 Is Dependent on
Calcium--
Since Hrs-2 is known to have calcium-sensitive
interactions with SNAP-25, we examined whether the interaction with
Eps15 is altered by calcium. Recombinant Eps15 was immobilized, and a
single concentration of Hrs-2 was added in the presence of increasing free Ca2+. As the concentration of Ca2+ was
increased, less Hrs-2 bound to Eps15 (Fig.
2). The half-maximal inhibition of Hrs-2
binding produced by Ca2+ was ~100 nM.
Ba2+ and Sr2+ (0.5 mM
concentrations) did not effect the binding of Hrs-2 to Eps15 (data not
shown). These data suggest that Ca2+ regulates the ability
of Hrs-2 and Eps15 to interact.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 2.
Effect of Ca2+ and SNAP-25 on the
interaction of Hrs-2 with Eps15. Ca2+ inhibits Hrs-2
binding to Eps15. A single concentration of Hrs-2 (0.6 µM) was incubated in the presence of increasing
concentrations of free Ca2+ and GST-Eps15 (0.22 µM) immobilized on glutathione-agarose. As the
Ca2+ concentration was increased the amount of Hrs-2 bound
to Eps15 decreased. The half-maximal inhibition was approximately 100 nM. This concentration approaches the resting level of
Ca2+ in the cell.
|
|
Eps15 and SNAP-25 Compete for Hrs-2 Binding--
The calcium
concentration necessary for half-maximal inhibition of Hrs-2/Eps15
binding is ~1000 × lower than that needed to inhibit
Hrs-2/SNAP-25 binding, suggesting that Eps15 and SNAP-25 do not
interact with Hrs-2 simultaneously. Additionally, since SNAP-25 is
involved in regulation of the exocytic machinery and Eps15 in the
endocytic machinery, it seems unlikely that they would bind to Hrs-2
simultaneously. To examine whether SNAP-25 and Eps15 interact with
Hrs-2 simultaneously, we incubated immobilized Hrs-2 with Eps15 and
increasing concentrations of SNAP-25 (Fig. 3). As the concentration of SNAP-25
increased, less Eps15 bound to Hrs-2. At 3 µM SNAP-25,
Eps15 binding was reduced by 90% indicating that while SNAP-25 and
Eps15 can both bind to Hrs-2, SNAP-25, and Eps15 do not bind to Hrs-2
simultaneously.

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 3.
SNAP-25 inhibits the interaction of Hrs-2
with Eps15. A constant concentration of Eps15 (0.1 µM) was incubated with increasing concentrations of
SNAP-25 and Hrs-2 (0.2 µM) immobilized on nickel-agarose.
As the concentration of SNAP-25 was increased the amount of Eps15 bound
decreased (lanes 1-5). Pixel values for Eps15 were 22,334, 17,606, 7807, 5888, and 2016, while pixel values for SNAP-25 were 1444, 16,071, 11,695, 26,251, 22,472. A Ponceau stain of the blot (Hrs-2)
shows equal loading of Hrs-2 coupled to agarose.
|
|
Hrs-2 and Eps15 Are Present on Endocytic Structures--
The
demonstration of a direct interaction between Hrs-2 and Eps15 suggests
that Hrs-2 may play a role in the endocytic machinery. Eps15 is
localized to components of the endocytic pathway (38, 42). Electron
microscopic studies have localized Eps15 at the rim of budding vesicles
(42), although biochemical studies indicate that Eps15 is present
throughout the endocytic pathway and undergoes cycles of association
and dissociation with membranes in multiple endocytic compartments
(38). Komada et al. (43) have reported that a homolog of
Hrs-2, Hrs, is localized on early endosomes in HeLa cells that are
overexpressing HA-tagged hrs. To understand where in the endocytic
pathway Hrs-2 and Eps15 may interact, we examined the ultrastructural
localization of Hrs-2 in neurons. As shown in Fig.
4, gold particles were localized on the
limiting membrane of MVBs (Fig. 4, A-C). Additional Hrs-2
immunoreactivity was found intracellularly although it did not appear
to be associated with any organelle or membrane and is therefore
assumed to be cytosolic. Differential centrifugation reveals that
approximately 75% of Hrs-2 is
cytosolic,2 and we observed
the majority of labeling on MVBs, suggesting that we cannot detect all
of the intracellular Hrs-2 with our technique. The presence of Hrs-2 on
limiting membranes of MVBs suggests an anatomical substrate for the
interaction of Hrs-2 with Eps15 on this organelle.

View larger version (176K):
[in this window]
[in a new window]
|
Fig. 4.
Ultrastructural localization of Hrs-2 in
neurons. Immunogold labeling of cerebellar neurons using an Hrs-2
antibody that was detected using silver-intensified gold and revealed
labeling associated with MVBs (A, B, and C) along
with some cytoplasmic and endosomal labeling (A).
Scale bar = 110 nm in A, and 220 nm in
B and C.
|
|
Eps15 Mediates the Hrs-2-induced Inhibition of Receptor-mediated
Endocytosis--
To examine whether Hrs-2 and Eps15 are coupled
functionally in the endocytic pathway we studied the effect of Hrs-2 on
the uptake of fluorescently labeled transferrin in HeLa cells (Fig. 5). The uptake of transferrin is
dependent on Eps15 (35, 39, 44). HeLa cells overexpressing GFP-tagged
Hrs-2 displayed markedly reduced transferrin uptake compared with
untransfected cells (Fig. 5, A versus
B). Quantification of these data revealed a significant inhibition of transferrin uptake in cells overexpressing Hrs-2 (Fig. 5,
bar graph). We expressed a GFP-Hrs-2 construct lacking the
Eps15-binding domain (GFP-Hrs-2 eps) in HeLa cells. In contrast to
the wild type Hrs-2 construct, the GFP-Hrs-2 eps construct was
cytosolic in localization, suggesting the need for the Eps15 binding
region of Hrs-2 for punctate localization (Fig. 5C), and transferrin uptake in cells expressing GFP-Hrs-2 eps was not
significantly different from untransfected cells (Fig. 5D).
We next overexpressed a portion of Hrs-2 containing only the
Eps15-binding region, Hrs-2(216-449). Hrs-2(216-449) was punctate in
localization and significantly inhibited transferrin uptake (Fig. 5,
E and F). Expression of the coiled-coil region of
Hrs-2 necessary for SNAP-25 interaction (Hrs-2 cc2) did not
significantly affect transferrin uptake (Fig. 5, G and
H). These data suggest that Hrs-2 can inhibit endocytosis and that its interaction with Eps15 is necessary for this function.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 5.
Effect of Hrs-2,
Hrs-2 eps, Hrs-2(216-449), and Hrs-2 cc2 on
receptor-mediated endocytosis in HeLa cells. GFP tagged Hrs-2,
Hrs-2 eps, Hrs-2(216-449), or Hrs-2 cc2 were transfected into HeLa
cells, and the uptake of Alexa594-labeled transferrin was examined.
A, wild-type GFP-Hrs-2 induced the appearance of large
intracellular compartments, and cells expressing GFP-Hrs-2
(n = 18) were deficient in the uptake of transferrin
compared with untransfected cells (B, bar
graph). Overexpression of GFP-hrs2 eps (n = 18)
resulted in cytosolic distribution of the protein (C) and
transferrin uptake that was not significantly different than
untransfected cells (D, bar graph).
Overexpression of Hrs-2(216-449) (n = 18) resulted in
a punctate localization (E) and transferrin uptake that was
significantly different from untransfected cells (F,
bar graph). Expression of Hrs-2 cc2 (n = 15)
resulted in a puntate localization (G) but did not
significantly inhibit transferrin uptake (H, bar graph). *
denotes significance using ANOVA with multiple comparisons
p 0.007.
|
|
Hrs-2 Inhibits Receptor-mediated Endocytosis by Competing with
-Adaptin for Eps15--
Hrs-2 binds to Eps15 through two domains,
one of which is also necessary for -adaptin binding (Fig. 1). Since
Eps15 regulates endocytosis through an interaction with -adaptin,
and Hrs-2 can regulate this process, we examined whether Hrs-2
regulates endocytosis by altering the Eps15/ -adaptin interaction.
Immobilized Eps15 was incubated with increasing concentrations of Hrs-2
in the presence and absence of -adaptin (Fig.
6A). In the absence of
-adaptin, Hrs-2 bound to Eps15 as we had observed in Fig. 1. In the
presence of -adaptin the binding of Hrs-2 to Eps15 was markedly
reduced (Fig. 6A, lanes 2-5 compared with 6-9).
These data suggest that Hrs-2 and -adaptin compete for binding to
Eps15.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 6.
-Adaptin competes with Hrs-2
for binding to Eps15 and suppresses Hrs-2 inhibition of
receptor-mediated endocytosis. Immobilized Eps15 was incubated
with increasing concentrations of Hrs-2 in the absence and presence of
-adaptin (A). In the absence of -adaptin (lanes
2-5), Hrs-2 bound to Eps15 as we had observed in Fig. 1. In the
presence of -adaptin (lanes 6-9), the binding of Hrs-2
to Eps15 was reduced (A). The concentration of immobilized
Eps15 was held constant at 0.3 µM. Lane 1 contains GST (0.6 µM) as a negative control. The
Ponceau-stained blot is shown as a loading control. Hrs-2
concentrations and integrated density values (×1000) were: lane
1, 4 µM, 1.73; lane 2, 1 µM, 2.08; lane 3, 2 µM, 7.58;
lane 4, 3 µM, 9.62; lane 5, 4 µM, 18.07; lane 6, 1 µM, 2.95;
lane 7, 2 µM, 2.11; lane 8, 3 µM, 2.56; lane 9, 4 µM, 2.51. These data suggest that Hrs-2 and -adaptin likely do not bind to
Eps15 simultaneously. B, expression of Hrs-2
(n = 15) significantly inhibited, while -adaptin
(n = 20) had no significant effect on transferrin
uptake (B). Transferrin uptake in cells coexpressing
-adaptin and Hrs-2 (n = 15) was not significantly
different than that found in untransfected cells. * denotes
significance using ANOVA with multiple comparisons p 0.005.
|
|
If Hrs-2 inhibits endocytosis by competition with -adaptin for Eps15
binding, then expression of -adaptin may rescue the inhibition of
endocytosis produced by expression of Hrs-2. Expression of Hrs-2
significantly inhibited, while -adaptin had no significant effect on
transferrin uptake (Fig. 6B). However, transferrin uptake was not significantly different than control in the cells coexpressing -adaptin and Hrs-2 (Fig. 6B). Since Hrs-2 apparently
competes with -adaptin for Eps15 binding, these data suggest a
mechanism in which Hrs-2 regulates endocytosis by binding to Eps15,
reducing its availability for -adaptin binding.
 |
DISCUSSION |
Using the two-hybrid approach we have found that Hrs-2 associates
with Eps15. We have confirmed a direct physical interaction using
recombinant fusion proteins and coimmunoprecipitation. Additionally, we
have shown that SNAP-25 competes with Eps15 for binding to recombinant
Hrs-2. The binding of the recombinant Hrs-2 protein to Eps15 is
calcium-dependent as the addition of calcium inhibits the
Hrs-2/Eps15 interaction. Furthermore, overexpression of full-length Hrs-2 or only the region necessary for Eps15 binding, but not a mutant
Hrs-2 lacking the Eps15-binding domain, inhibits the endocytosis of
transferrin in HeLa cells. Moreover, both Eps15 and Hrs-2 are localized
to components of the endocytic pathway. Thus, Hrs-2 is involved in
endocytic processes through interactions with Eps15. Since Hrs-2 is
involved in regulation of exocytic complex assembly and is unable to
interact with SNAP-25 and Eps15 simultaneously, these data suggest that
Hrs-2 may provide communication between endo- and exocytic processes by
regulated interactions with the molecular machinery underlying both functions.
The in vitro binding of recombinant Hrs-2 and Eps15
demonstrates a direct interaction in the absence of other protein
components. The EC50 of the Hrs-2/Eps15 interaction is
approximately 1.8 µM. Thus, the interaction of Hrs-2 with
Eps15 in vitro is of lower apparent affinity than that of
the Hrs-2 with SNAP-25. This may reflect a more transient in
vivo Hrs-2/Eps15 interaction or may be related to the ability of
SNAP-25 to displace Eps15 from Hrs-2 (see below).
The binding site of Eps15 on Hrs-2 is in a region between the FYVE
finger and the first coiled-coil domain, a different region from that
involved in SNAP-25 binding (11). The inhibition of Eps15 binding to
Hrs-2 by SNAP-25 was therefore unexpected based on the difference in
their binding site localization. Conformational changes due to SNAP-25
binding may result in an altered affinity of Hrs-2 for Eps15. The
ability of SNAP-25 to inhibit Eps15 binding to Hrs-2 suggests that
Hrs-2 may toggle between SNAP-25 and Eps15, perhaps based on local
calcium concentrations (see below). Hrs-2 binds to two distinct regions
of Eps15, the coiled-coil and the -adaptin-binding region in the
COOH-terminal of Eps15. The coiled coil region of Eps15 in responsible
for homoligomerization (45) which has been shown to result in increased
affinity of Eps15 for -adaptin (46). These data suggest that the
Hrs-2/Eps15 interaction may alter the oligomeric state of Eps15 and/or
its association with -adaptin, or that Hrs-2 may not interact with the fraction of Eps15 that is in a complex with -adaptin. Since the
Eps15/ -adaptin association is required for endocytosis (35, 39), the
inhibition of this interaction by Hrs-2 would be expected to inhibit
endocytosis and may underlie the inhibition of endocytosis produced by
overexpression of Hrs-2 (see below).
Calcium inhibits the binding of Eps15 to Hrs-2. Secondary structure
predictions reveal that Hrs-2 may form multiple helix-loop-helix structures and could coordinate divalent cations in its dual zinc finger region (10). Additionally, Eps15 may form helix-loop-helix structures and has been suggested to bind calcium (33). Neither Hrs-2
nor Eps15 have been formally shown to bind calcium. However, both
proteins have potential divalent cation binding sites and are altered
in their ability to interact with other proteins when calcium is
present. The half-maximal calcium concentration for the inhibition of
Hrs-2 Eps15 binding is approximately 100 nM, which
approaches the resting level of calcium in the cell. Thus, either
compartmentalization within the cell produces low calcium concentrations near endocytic structures or, perhaps more likely, the
binding of Hrs-2 to Eps15 is finely regulated by very small alterations
in intracellular calcium. There is a 1000-fold difference in the
calcium sensitivity of the binding of Hrs-2 to Eps15 compared with the
Hrs-2/SNAP-25 interaction. The mechanism of the differential sensitivity to calcium may involve differences in Hrs-2, SNAP-25, and/or Eps15 protein conformation due to the presence of calcium. Alternatively, calcium may alter the oligomeric state of Hrs-2 or
Eps15.
Eps15 has been shown to be associated with components of the endocytic
pathway by biochemical fractionation as well as electron microscopy
(38, 42). Initially, Eps15 was suggested to be present only on the
edges of membrane invaginations (42), although recent data suggest that
it is associated with both early and late endosomes during epidermal
growth factor receptor-stimulated endocytosis (38). We have observed
Hrs-2 immunoreactivity on the limiting membrane of MVBs in nerve
terminals in the brain. MVBs are a sorting organelle in the late
endocytic pathway that function to separate proteins destined for
degradation in the lysosome from those that recycle back to the Golgi
(e.g. mannose 6-phosphate receptor) or to the plasma
membrane (e.g. transferrin receptor) (47-50). Examination
of wild type and kinase mutant epidermal growth factor receptor
internalization suggests that mutant receptors are found on the MVB
limiting membrane and are recycled back to the plasma membrane, while
wild type receptors are found in luminal MVB vesicles and are degraded
(48). We have not observed labeling for Hrs-2 on the internal vesicles
of MVBs. These data suggest that Hrs-2 is involved in functions related
to the trafficking of the MVBs themselves or to sorting in the MVB compartment.
In addition to its localization on endocytic structures, we expected to
find Hrs-2 immunoreactivity on the plasma membrane or components of the
exocytic pathway due to its interaction with SNAP-25. We have observed
Hrs-2 immunoreactivity in nerve terminals and cell bodies that appeared
not to be associated with membranous structures. Negative
immunohistochemical data is difficult to interpret. It is possible that
the binding of Hrs-2 to SNAP-25, as would likely occur on the plasma
membrane, masks the epitope for our antibody resulting in a lack of
labeling on this structure.
Expression of Hrs-2 or the region of Hrs-2 that is necessary for Eps15
binding (Hrs-2(216-449)) inhibits receptor-mediated endocytosis in
HeLa cells. Hrs-2 lacking the Eps15-binding domain (Hrs-2 Eps15) or
the Hrs-2 fragment (cc2) necessary for binding to SNAP-25 do not
inhibit receptor-mediated endocytosis in HeLa cells. Thus, the
mechanism by which Hrs-2 inhibits endocytosis involves Eps15 or its
downstream effectors. Eps15 is known to bind to -adaptin, an
interaction required for receptor-mediated endocytosis (35, 39). We
observed that Hrs-2 and -adaptin compete for binding to Eps15 and
that the Hrs-2-induced disruption of endocytosis is rescued by
-adaptin. The interaction of Hrs-2 with Eps15 might be an upstream
event (prior to Eps15/ -adaptin binding) in the biochemical pathway
that results in endocytosis and Hrs-2 would therefore be well
positioned to act on this process in a regulatory manner. Local calcium
concentration, lipid binding, or post-translational modifications may
regulate Hrs-2 itself. Endocytosis is an energy-dependent
process with at least two ATP-dependent steps (51). Thus,
the ATPase activity of Hrs-2 may provide for ATP-dependent
alterations in protein conformation or protein complex assembly/disassembly that are necessary for endocytosis. The molecular mechanism by which Hrs-2 inhibits endocytosis appears to be similar to
that in that it uses exocytosis; Hrs-2 inhibits protein complex formation (Eps15/ -adaptin or syntaxin-SNAP-25/VAMP) by competing with one of the complex constituents.
Hrs-2 can regulate both exo- and endocytosis and the process regulated
by Hrs-2 at any one time likely depends on the protein machinery with
which it is currently interacting. The regulation of these interactions
may depend on local calcium concentrations that could switch Hrs-2 from
interacting with SNAP-25 to Eps15. Another potential role for Hrs-2 may
be in the regulation of Q-SNARE sorting by binding to and excluding
SNAP-25 and/or the SNAP-25·syntaxin complex from the endocytic
pathway when it is being used for recycling synaptic vesicle membrane
and constituent proteins. This would enable sorting of plasma membrane
Q-SNAREs away from vesicle constituents following fusion, allowing for
segregation of compartmental proteins and membrane composition.
Although neuronal cells rely heavily on exo- and endocytosis for
synaptic transmission, these processes must be coupled in all
eukaryotic cells. Hrs-2 is found in neurons as well as in non-neuronal
cells where it interacts with SNAP-23, a SNAP-25 homolog (11). The
localization of Hrs-2 on endocytic structures as well as its ability to
interact with SNAP-25 (presumably on the plasma membrane) suggests that
it may be in a position to regulate both exo- and endocytosis on the
membranes involved in these trafficking events. Hrs-2 may act in
endocytosis during two stages: an early stage involving coordination
through calcium-dependent protein interactions with
essential components of both processes and a later stage that is
non-Eps15/ -adaptin-dependent and involves trafficking of MVBs.
Efficient linkage of the exocytic and endocytic machinery requires that
the coupling signal be transient, able to interact with both processes,
and able to act at a critical stage in either process. Hrs-2, through
its interactions with SNAP-25 and Eps15, may play a regulatory function
on the molecular machinery underlying both exo- and endocytosis. The
role of Hrs-2 is likely dependent on the local calcium, lipid, and
nucleotide microenvironment. The possibility that Hrs-2 toggles between
SNAP-25 and Eps15 suggests a mechanism by which this coupling signal
may occur.
 |
Acknowlegments |
We thank Drs. PerPalo DiFiore and Lisa Salcini
for pCEV and pGEX Eps15 full-length constructs, and Dr. Alexandre
Benmerah for Eps15 truncation constructs. We also thank Bill Evans for help throughout these studies, Drs. Sally Kim, Ben Strowbridge, Tom
Vida, and Neal Waxham for helpful discussions, and Drs. Vida, Waxham
and Vivian Siegel for critical comments on the manuscript.
 |
FOOTNOTES |
*
This work was supported in part by the Mallinckrodt
Foundation and National Institutes of Health Grant MH058920.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Neurobiology
and Anatomy, University of Texas Medical School, 6431 Fannin St., Rm.
7.208, Houston, TX 77030. Tel.: 713-500-5614; Fax: 713-500-0623; E-mail: abean@nba19.med.uth.tmc.edu.
2
A. J. Bean, unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
SNAP-25, synaptosomal associated protein of 25 kDa;
Eps15, epidermal growth
factor receptor substrate 15;
VAMP, vesicle-associated membrane
protein;
Hrs-2, hepatocyte growth factor-regulated tyrosine kinase
substrate 2;
GST, glutathione S-transferase;
PBS-T, phosphate-buffered saline and 0.05% Tween 20;
SDS-PAGE, sodium dodecyl
sulfate-polyacrylamide electrophoresis;
MVB, multivesicular body.
 |
REFERENCES |
| 1.
|
Rothman, J. E.
(1994)
Nature
372,
55-63[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Scheller, R. H.
(1995)
Neuron
14,
893-897[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Sudhof, T. C.
(1995)
Nature
375,
645-653[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Sollner, T.,
Bennett, M. K.,
Whiteheart, S. W.,
Scheller, R. H.,
and Rothman, J. E.
(1993)
Cell
75,
409-418[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Oyler, G. A.,
Higgins, G. A.,
Hart, R. A.,
Battenberg, E.,
Billingsley, M.,
Bloom, F. E.,
and Wilson, M. C.
(1989)
J. Cell Biol.
109,
3039-3052[Abstract/Free Full Text]
|
| 6.
|
Chapman, E. R.,
An, S.,
Barton, N.,
and Jahn, R.
(1994)
J. Biol. Chem.
269,
27427-27432[Abstract/Free Full Text]
|
| 7.
|
Fasshauer, D.,
Eliason, W. K.,
Brunger, A. T.,
and Jahn, R.
(1998)
Biochemistry
37,
10354-10362[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Sutton, R. B.,
Fasshauer, D.,
Jahn, R.,
and Brunger, A. T.
(1998)
Nature
395,
347-353[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Weber, T.,
Zemelman, B. V.,
McNew, J. A.,
Westermann, B.,
Gmachl, M.,
Parlati, F.,
Sollner, T. H.,
and Rothman, J. E.
(1998)
Cell
92,
759-772[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Bean, A. J.,
Seifert, R.,
Chen, Y. A.,
Sacks, R.,
and Scheller, R. H.
(1997)
Nature
385,
826-829[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Tsujimoto, S.,
and Bean, A. J.
(2000)
J. Biol. Chem
275,
2938-2942[Abstract/Free Full Text]
|
| 12.
|
Artalejo, C. R.,
Henley, J. R.,
McNiven, M. A.,
and Palfrey, H. C.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
8328-8332[Abstract/Free Full Text]
|
| 13.
|
Burgoyne, R. D.
(1995)
Pflugers Arch.
430,
213-219[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
De Camilli, P.,
and Takei, K.
(1996)
Neuron
16,
481-486[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Klingauf, J.,
Kavalali, E. T.,
and Tsien, R. W.
(1998)
Nature
394,
581-585[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Kavalali, E. T.,
Klingauf, J.,
and Tsien, R. W.
(1999)
Philos. Trans. R. Soc. Lond. B Biol. Sci.
354,
337-346[Abstract/Free Full Text]
|
| 17.
|
Koenig, J. H.,
and Ikeda, K.
(1996)
J. Cell Biol.
135,
797-808[Abstract/Free Full Text]
|
| 18.
|
Koenig, J. H.,
Yamaoka, K.,
and Ikeda, K.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
12677-12682[Abstract/Free Full Text]
|
| 19.
|
Koenig, J. H.,
and Ikeda, K.
(1999)
J. Neurophys.
81,
1495-1505[Abstract/Free Full Text]
|
| 20.
|
Ryan, T. A.,
Smith, S. J.,
and Reuter, H.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
5567-5571[Abstract/Free Full Text]
|
| 21.
|
Smith, C.,
and Neher, E.
(1997)
J. Cell Biol.
139,
885-894[Abstract/Free Full Text]
|
| 22.
|
Betz, W. J.,
and Angleson, J. K.
(1998)
Annu. Rev. Physiol.
60,
347-363[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Schmid, S. L.
(1997)
Annu. Rev. Biochem.
66,
511-548[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Hao, W.,
Luo, Z.,
Zheng, L.,
Prasad, K.,
and Lafer, E. M.
(1999)
J. Biol. Chem.
274,
22785-22794[Abstract/Free Full Text]
|
| 25.
|
Herskovits, J. S.,
Burgess, C. C.,
Obar, R. A.,
and Vallee, R. B.
(1993)
J. Cell Biol.
122,
565-578[Abstract/Free Full Text]
|
| 26.
|
Santini, F.,
Marks, M. S.,
and Keen, J. H.
(1998)
Mol. Biol. Cell
9,
1177-1194[Abstract/Free Full Text]
|
| 27.
|
Schmid, S. L.,
McNiven, M. A.,
and De Camilli, P.
(1998)
Curr. Opin. Cell Biol.
10,
504-512[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Sever, S.,
Muhlberg, A. B.,
and Schmid, S. L.
(1999)
Nature
398,
481-486[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Takei, K.,
Slepnev, V. I.,
Houcke, V.,
and De Camilli, P.
(1999)
Nat. Cell Biol.
1,
33-39[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Wong, W. T.,
Schumacher, C.,
Salcini, A. E.,
Romano, A.,
Castagnino, P.,
Pelicci, P. G.,
and Di Fiore, P.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
9530-9534[Abstract/Free Full Text]
|
| 31.
|
Tang, H. Y.,
Munn, A.,
and Cai, M.
(1997)
Mol. Cell. Biol.
17,
4294-4304[Abstract]
|
| 32.
|
Paoluzi, S.,
Castagnoli, L.,
Lauro, I.,
Salcini, A. E.,
Coda, L.,
Fre, S.,
Confalonieri, S.,
Pelicci, P. G.,
Di Fiore, P. P.,
and Cesareni, G.
(1998)
EMBO J.
17,
6541-6550[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Fazioli, F.,
Minichiello, L.,
Matoskova, B.,
Wong, W. T.,
and Di Fiore, P. P.
(1993)
Mol. Cell. Biol.
13,
5814-5828[Abstract/Free Full Text]
|
| 34.
|
Chen, H.,
Fre, S.,
Slepnev, V. I.,
Capua, M. R.,
Takei, K.,
Butler, M. H.,
Di Fiore, P. P.,
and De Camilli, P.
(1998)
Nature
394,
793-797[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Carbone, R.,
Fre, S.,
Iannolo, G.,
Belleudi, F.,
Mancini, P.,
Pelicci, P. G.,
Torrisi, M. R.,
and Di Fiore, P. P.
(1997)
Cancer Res.
57,
5498-5504[Abstract/Free Full Text]
|
| 36.
|
Salcini, A. E.,
Confalonieri, S.,
Doria, M.,
Santolini, E.,
Tassi, E.,
Minenkova, O.,
Cesareni, G.,
Pelicci, P. G.,
and Di Fiore, P. P.
(1997)
Genes Dev.
11,
2239-2249[Abstract/Free Full Text]
|
| 37.
|
Sengar, A. S.,
Wang, W.,
Bishay, J.,
Cohen, S.,
and Egan, S. E.
(1999)
EMBO J.
18,
1159-1171[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Torrisi, M. R.,
Lotti, L. V.,
Belleudi, F.,
Gradini, R.,
Salcini, A. E.,
Confalonieri, S.,
Pelicci, P. G.,
and Di Fiore, P. P.
(1999)
Mol. Biol. Cell
10,
417-434[Abstract/Free Full Text]
|
| 39.
|
Benmerah, A.,
Lamaze, C.,
Begue, B.,
Schmid, S. L.,
Dautry-Varsat, A.,
and Cerf-Bensussan, N.
(1998)
J. Cell Biol.
140,
1055-1062[Abstract/Free Full Text]
|
| 40.
|
Wendland, B.,
and Emr, S. D.
(1998)
J. Cell Biol.
141,
71-84[Abstract/Free Full Text]
|
| 41.
|
Tsujimoto, S.,
Pelto-Huikko, M.,
Aitola, M.,
Meister, B.,
Vik-Mo, E. O.,
Davanger, S.,
Scheller, R. H.,
and Bean, A. J.
(1999)
Eur. J. Neurosci.
11,
3047-3063[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Tebar, F.,
Sorkina, T.,
Sorkin, A.,
Ericsson, M.,
and Kirchhausen, T.
(1996)
J. Biol. Chem.
271,
28727-28730[Abstract/Free Full Text]
|
| 43.
|
Komada, M.,
Masaki, R.,
Yamamoto, A.,
and Kitamura, N.
(1997)
J. Biol. Chem.
272,
20538-20544[Abstract/Free Full Text]
|
| 44.
|
Benmerah, A.,
Bayrou, M.,
Cerf-Bensussan, N.,
and Dautry-Varsat, A.
(1999)
J. Cell Sci.
112,
1303-1311[Abstract]
|
| 45.
|
Cupers, P.,
ter Haar, E.,
Boll, W.,
and Kirchhausen, T.
(1997)
J. Biol. Chem.
272,
33430-33434[Abstract/Free Full Text]
|
| 46.
|
Tebar, F.,
Confalonieri, S.,
Carter, R. E.,
Di Fiore, P. P.,
and Sorkin, A.
(1997)
J. Biol. Chem.
272,
15413-15418[Abstract/Free Full Text]
|
| 47.
|
Hirst, J.,
Futter, C. E.,
and Hopkins, C. R.
(1998)
Mol. Biol. Cell
9,
809-816[Abstract/Free Full Text]
|
| 48.
|
Felder, S.,
Miller, K.,
Moehren, G.,
Ullrich, A.,
Schlessinger, J.,
and Hopkins, C. R.
(1990)
Cell
61,
623-634[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Futter, C. E.,
Pearse, A.,
Hewlett, L. J.,
and Hopkins, C. R.
(1996)
J. Cell Biol.
132,
1011-1023[Abstract/Free Full Text]
|
| 50.
|
Odorizzi, G.,
Babst, M.,
and Emr, S. D.
(1998)
Cell
95,
847-858[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Schmid, S. L.,
and Smythe, E.
(1991)
J. Cell Biol.
114,
869-880[Abstract/Free Full Text]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. A. Parachoniak and M. Park
Distinct Recruitment of Eps15 via Its Coiled-coil Domain Is Required For Efficient Down-regulation of the Met Receptor Tyrosine Kinase
J. Biol. Chem.,
March 27, 2009;
284(13):
8382 - 8394.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Roxrud, C. Raiborg, N. M. Pedersen, E. Stang, and H. Stenmark
An endosomally localized isoform of Eps15 interacts with Hrs to mediate degradation of epidermal growth factor receptor
J. Cell Biol.,
March 24, 2008;
180(6):
1205 - 1218.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T.-W. Koh, V. I. Korolchuk, Y. P. Wairkar, W. Jiao, E. Evergren, H. Pan, Y. Zhou, K. J.T. Venken, O. Shupliakov, I. M. Robinson, et al.
Eps15 and Dap160 control synaptic vesicle membrane retrieval and synapse development
J. Cell Biol.,
July 10, 2007;
178(2):
309 - 322.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Bouamr, B. R. Houck-Loomis, M. De Los Santos, R. J. Casaday, M. C. Johnson, and S. P. Goff
The C-Terminal Portion of the Hrs Protein Interacts with Tsg101 and Interferes with Human Immunodeficiency Virus Type 1 Gag Particle Production
J. Virol.,
March 15, 2007;
81(6):
2909 - 2922.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Yan, W. Sun, P. Kujala, Y. Lotfi, T. A. Vida, and A. J. Bean
CART: An Hrs/Actinin-4/BERP/Myosin V Protein Complex Required for Efficient Receptor Recycling
Mol. Biol. Cell,
May 1, 2005;
16(5):
2470 - 2482.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Kobayashi, N. Tanaka, H. Asao, S. Miura, M. Kyuuma, K. Semura, N. Ishii, and K. Sugamura
Hrs, a Mammalian Master Molecule in Vesicular Transport and Protein Sorting, Suppresses the Degradation of ESCRT Proteins Signal Transducing Adaptor Molecule 1 and 2
J. Biol. Chem.,
March 18, 2005;
280(11):
10468 - 10477.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Komada and N. Kitamura
The Hrs/STAM Complex in the Downregulation of Receptor Tyrosine Kinases
J. Biochem.,
January 1, 2005;
137(1):
1 - 8.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. N. Hislop, A. Marley, and M. von Zastrow
Role of Mammalian Vacuolar Protein-sorting Proteins in Endocytic Trafficking of a Non-ubiquitinated G Protein-coupled Receptor to Lysosomes
J. Biol. Chem.,
May 21, 2004;
279(21):
22522 - 22531.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Mizuno, K. Kawahata, A. Okamoto, N. Kitamura, and M. Komada
Association with Hrs Is Required for the Early Endosomal Localization, Stability, and Function of STAM
J. Biochem.,
March 1, 2004;
135(3):
385 - 396.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L.-F. Seet, N. Liu, B. J. Hanson, and W. Hong
Endofin Recruits TOM1 to Endosomes
J. Biol. Chem.,
February 6, 2004;
279(6):
4670 - 4679.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Polo, S. Confalonieri, A. E. Salcini, and P. P. Di Fiore
EH and UIM: Endocytosis and More
Sci. Signal.,
December 16, 2003;
2003(213):
re17 - re17.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Hinrichsen, J. Harborth, L. Andrees, K. Weber, and E. J. Ungewickell
Effect of Clathrin Heavy Chain- and {alpha}-Adaptin-specific Small Inhibitory RNAs on Endocytic Accessory Proteins and Receptor Trafficking in HeLa Cells
J. Biol. Chem.,
November 14, 2003;
278(46):
45160 - 45170.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Petiot, J. Faure, H. Stenmark, and J. Gruenberg
PI3P signaling regulates receptor sorting but not transport in the endosomal pathway
J. Cell Biol.,
September 15, 2003;
162(6):
971 - 979.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Mizuno, K. Kawahata, M. Kato, N. Kitamura, and M. Komada
STAM Proteins Bind Ubiquitinated Proteins on the Early Endosome via the VHS Domain and Ubiquitin-interacting Motif
Mol. Biol. Cell,
September 1, 2003;
14(9):
3675 - 3689.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. D. Fisher, B. Wang, S. L. Alam, D. S. Higginson, H. Robinson, W. I. Sundquist, and C. P. Hill
Structure and Ubiquitin Binding of the Ubiquitin-interacting Motif
J. Biol. Chem.,
August 1, 2003;
278(31):
28976 - 28984.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Sun, Q. Yan, T. A. Vida, and A. J. Bean
Hrs regulates early endosome fusion by inhibiting formation of an endosomal SNARE complex
J. Cell Biol.,
July 7, 2003;
162(1):
125 - 137.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Lu, L. W. Hope, M. Brasch, C. Reinhard, and S. N. Cohen
TSG101 interaction with HRS mediates endosomal trafficking and receptor down-regulation
PNAS,
June 24, 2003;
100(13):
7626 - 7631.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. G. Bache, C. Raiborg, A. Mehlum, and H. Stenmark
STAM and Hrs Are Subunits of a Multivalent Ubiquitin-binding Complex on Early Endosomes
J. Biol. Chem.,
March 28, 2003;
278(14):
12513 - 12521.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. Chetkovich, R. C. Bunn, S.-H. Kuo, Y. Kawasaki, M. Kohwi, and D. S. Bredt
Postsynaptic Targeting of Alternative Postsynaptic Density-95 Isoforms by Distinct Mechanisms
J. Neurosci.,
August 1, 2002;
22(15):
6415 - 6425.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Heidelberger
ATP Is Required at an Early Step in Compensatory Endocytosis in Synaptic Terminals
J. Neurosci.,
September 1, 2001;
21(17):
6467 - 6474.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Shukla, H. Hager, T. J. Corydon, A. J. Bean, R. Dahl, Z. Vajda, H. Li, H. J. Hoffmann, and S. Nielsen
SNAP-25-associated Hrs-2 protein colocalizes with AQP2 in rat kidney collecting duct principal cells
Am J Physiol Renal Physiol,
September 1, 2001;
281(3):
F546 - F556.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|